# Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

> **NCT03454035** · PHASE1 · RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 45 (estimated)

## Conditions studied

- Tumor, Solid
- Pancreatic Cancer
- Melanoma

## Interventions

- **DRUG:** Ulixertinib
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT03454035
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-01-30
- **Primary completion:** 2026-07-15
- **Final completion:** 2026-11-24
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03454035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03454035, "Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03454035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*